Medivir AB announced that Medivir’s partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348.
The strategic collaboration between Curadh MTR Inc. and SHINE Technologies marks a pivotal moment in the advancement of cancer therapies.
Norgine is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer.
Biosyngen Pte Ltd announced that the U.S. FDA has cleared the Investigational New Drug application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and other advanced solid tumors.
Verona Pharma plc, announces the US Food and Drug Administration has accepted for review the Company’s New Drug Application seeking approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Crossject, a specialty pharma company developing needle-free autoinjectors for emergency situations, announces a significant improvement in its ESG Gaïa rating, achieving a score of 73/100.
Crossject announces significant improvement in Gaïa ESG rating Read More »
Samsung Bioepis Co., Ltd. announced that it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelarai, marking a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the United States, Canada, European Economic Area, Switzerland and United Kingdom.
Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate Read More »
Mirati Therapeutics, Inc.® presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in patients with non-small cell lung cancer harboring a KRASG12C mutation.
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a Capital Markets Day on October 17, 2023.
Save the date: IRLAB holds Capital Markets Day on October 17, 2023 Read More »
PeproMene Bio, Inc. announced that the first dose cohort of its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma clinical trial of PMB-CT01 has been completed.
